The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care

Feldmann, 1996, Role of cytokines in rheumatoid arthritis, Annual Review of Immunology, 14, 397, 10.1146/annurev.immunol.14.1.397 Smolen, 2003, Therapeutic strategies for rheumatoid arthritis, Nature Reviews Drug Discovery, 2, 473, 10.1038/nrd1109 Mallya, 1982, Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentrations of C-reactive protein and erythrocyte sedimentation rate, Journal of Rheumatology, 9, 224 Aletaha, 2006, The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey, Rheumatology, 45, 1133, 10.1093/rheumatology/kel074 van der Heijde, 1992, Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis, Annals of Rheumatic Disease, 51, 177, 10.1136/ard.51.2.177 van Leeuwen, 1997, Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system, Journal of Rheumatology, 24, 20 Aletaha, 2005, Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score, Arthritis Research, 7, R796, 10.1186/ar1740 van Leeuwen, 1994, Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants, Journal of Rheumatology, 21, 425 Pincus, 1984, Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years, Arthritis and Rheumatism, 27, 864, 10.1002/art.1780270805 Sokka, 1999, Work disability in rheumatoid arthritis 10 years after the diagnosis, Journal of Rheumatology, 26, 1681 Pincus, 1992, Early mortality in RA predicted by poor clinical status, Bulletin on the Rheumatic Diseases, 41, 1 Aletaha, 2006, Measuring function in rheumatoid arthritis: identifying reversible and irreversible components, Arthritis and Rheumatism, 54, 2784, 10.1002/art.22052 Drossaers-Bakker, 1999, Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time, Arthritis and Rheumatism, 42, 1854, 10.1002/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F Welsing, 2001, The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis, Arthritis and Rheumatism, 44, 2009, 10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L Smolen, 2005, Evidence of Radiographic Benefit of Infliximab Plus Methotrexate in Rheumatoid Arthritis Patients Who Had No Clinical Improvement: A Detailed Subanalysis of the ATTRACT Trial, Arthritis and Rheumatism, 52, 1020, 10.1002/art.20982 Breedveld, 2006, The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment, Arthritis and Rheumatism, 54, 26, 10.1002/art.21519 Keystone, 2004, Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial, Arthritis and Rheumatism, 50, 1400, 10.1002/art.20217 Klareskog, 2004, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet, 363, 675, 10.1016/S0140-6736(04)15640-7 Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, New England Journal of Medicine, 343, 1594, 10.1056/NEJM200011303432202 St Clair, 2004, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial, Arthritis and Rheumatism, 50, 3432, 10.1002/art.20568 Cohen, 2006, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy, Arthritis and Rheumatism, 54, 2739 Kremer, 2006, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial, Annals of Internal Medicine, 144, 865, 10.7326/0003-4819-144-12-200606200-00003 Goekoop-Ruiterman, 2005, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial, Arthritis and Rheumatism, 52, 3381, 10.1002/art.21405 Grigor, 2004, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, Lancet, 364, 263, 10.1016/S0140-6736(04)16676-2 Boers, 1994, WHO and ILAR core endpoints for symptom modifying antirheumatic drugs in RA clinical trials, Journal of Rheumatology, 21, 86 Felson, 1993, The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials, Arthritis and Rheumatism, 36, 729, 10.1002/art.1780360601 Scott, 1992, Disease activity in rheumatoid arthritis -preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research, Clinical and Experimental Rheumatology, 10, 521 Felson, 1995, American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis, Arthritis and Rheumatism, 38, 727, 10.1002/art.1780380602 Van der Heijde, 1993, Development of a Disease activity score based on judgement in clinical practice by rheumatologists, Journal of Rheumatology, 20, 579 van Gestel, 1998, Validation of rheumatoid arthritis improvement criteria that include simplified joint counts, Arthritis and Rheumatism, 41, 1845, 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K Pincus, 2000, An infrastructure of patient questionnaires at each rheumatology visit: improving efficiency and documenting care. (Editorial), Journal of Rheumatology, 27, 2727 Aletaha, 2006, The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases, Rheumatic Diseases Clinics of North America, 32, 9, 10.1016/j.rdc.2005.09.005 Siegel, 2005, Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis. Argument in Favor, Arthritis and Rheumatism, 52, 1637, 10.1002/art.21243 Boers, 2005, Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis. Argument in Opposition, Arthritis and Rheumatism, 52, 1642, 10.1002/art.21106 Aletaha, 2006, The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers, Arthritis and Rheumatism, 54, 377, 10.1002/art.21554 Goldsmith, 1993, Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patients and trial profiles, Journal of Rheumatology, 20, 561 van der Heijde, 1990, Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score, Annals of Rheumatic Diseases, 49, 916, 10.1136/ard.49.11.916 van Gestel, 1996, Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria, Arthritis and Rheumatism, 39, 34, 10.1002/art.1780390105 Egan, 2003, Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research, Archives of Internal Medicine, 163, 681, 10.1001/archinte.163.6.681 Rachmani, 2005, Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study, Journal of the American Society of Nephrology, 16, S22, 10.1681/ASN.2004110965 Eberl, 2000, Development of a disease activity index for the assessment of reactive arthritis (DAREA), Rheumatology, 39, 148, 10.1093/rheumatology/39.2.148 Smolen, 2003, A Simplified Disease Activity Index for Rheumatoid Arthritis For Use In Clinical Practice, Rheumatology, 42, 244, 10.1093/rheumatology/keg072 Wolfe, 1994, The clinical and research significance of the erythrocyte sedimentation rate, Journal of Rheumatology, 21, 1227 Wolfe, 2001, The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness, Journal of Rheumatology, 28, 1817 Aletaha, 2005, Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states, Arthritis and Rheumatism, 52, 2625, 10.1002/art.21235 Aletaha, 2005, The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis, Clinical and Experimental Rheumatology, 23, S100 Aletaha, 2005, Functional limitation in rheumatoid arthritis: how much is reversible?, Arthritis and Rheumatism, 52 Felson, 2007, A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response, Arthritis and Rheumatism, 57, 193, 10.1002/art.22552 Soubrier, 2006, Which Variables Best Predict Change in Rheumatoid Arthritis Therapy in Daily Clinical Practice?, Journal of Rheumatology Lissiane, 2006, The new indices Sdai and Cdai in early arthritis: similar performance to the Das28 index, Arthritis and Rheumatism, 54, S206 Lian, 2006, Clinical Disease Activity Index (CDAI) is a valid instrument for assessing disease activity amongst oriental early rheumatoid arthritis (ERA) patients, Arthritis and Rheumatism, 54, S377 Makinen, 2005, Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?, Annals of Rheumatic Diseases, 64, 1410, 10.1136/ard.2005.037333 van der Heijde, 2005, Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results, Annals of Rheumatic Diseases, 64, 1582, 10.1136/ard.2004.034371 Mierau, 2007, Assessing remission in clinical practice, Rheumatology, 46, 975, 10.1093/rheumatology/kem007 Molenaar, 2002, Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission, Journal of Rheumatology, 29, 267 Aletaha, 2006, Remission of rheumatoid arthritis: should we care about definitions?, Clinical and Experimental Rheumatology, S045 Maini, 2006, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis and Rheumatism, 54, 2817, 10.1002/art.22033 Aletaha, 2006, Definition of Moderate and Major Response for Disease Activity Indices in Rheumatoid Arthritis (RA), Annals of Rheumatic Diseases, 65, 692 Smolen, 2006, Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial, Arthritis and Rheumatism, 54, 702, 10.1002/art.21678 Smolen, 2003, A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures, Clinical and Experimental Rheumatology, 21, S209